Evidence map›Paper›PMID 40429390›Full record

ReviewJournal of clinical medicine2025

Prevalence, Diagnosis, and Treatment of Cardiac Tumors: A Narrative Review.

Mohamed Rahouma, Hosny Mohsen, Mahmoud Morsi, Sherif Khairallah, Lilian Azab, Maya Abdelhemid, Akshay Kumar, Magdy M El-Sayed Ahmed

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohamed RahoumaCardiothoracic Surgery Department, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY 10065, USA.ORCID 0000-0002-8678-2060
Hosny MohsenDepartment of Cardiothoracic Surgery, Faculty of Medicine, Beni Suef University, Beni Suef 62511, Egypt.ORCID 0009-0005-1265-4305
Mahmoud MorsiCardiothoracic Surgery Department, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY 10065, USA.ORCID 0000-0002-9140-7134
Sherif KhairallahCardiothoracic Surgery Department, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY 10065, USA.
Lilian AzabCardiothoracic Surgery Department, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY 10065, USA.
Maya AbdelhemidCardiothoracic Surgery Department, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY 10065, USA.
Akshay KumarCardiothoracic Surgery Department, NYU Langone Health, New York, NY 10016, USA.
Magdy M El-Sayed AhmedCardiothoracic Surgery Department, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0002-0729-8829

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac tumors, though rare, present significant diagnostic and therapeutic challenges due to their heterogeneous nature and anatomical complexity. This narrative review synthesizes current evidence on prevalence, diagnostic modalities, and management strategies for primary and metastatic cardiac tumors. Echocardiography, cardiac MRI, and CT remain cornerstone imaging tools for differentiating tumors from non-neoplastic masses, while advances in PET/CT and tissue characterization techniques refine staging and treatment planning. Surgical resection with clear margins (R0) is critical for resectable tumors, particularly benign myxomas, though malignant tumors like sarcomas require multimodal approaches combining surgery, radiotherapy, and systemic therapies. Emerging strategies such as heart autotransplantation and staged resections offer promise for complex cases, while oligometastatic disease management highlights the role of stereotactic radiotherapy and immunotherapy. Key challenges include standardizing resection margins, optimizing neoadjuvant therapies, and addressing high recurrence rates in malignancies. Future directions emphasize integrating AI-driven imaging analysis, molecular biomarkers, and genomic profiling to personalize therapies, alongside global registries to enhance data on rare tumors. Equitable access to advanced diagnostics and multidisciplinary collaboration are essential to improve outcomes. This review underscores the need for standardized guidelines, technological innovation, and patient-centered research to address gaps in cardiac oncology.

Indexed as

autotransplantationcardiac tumorsmultimodal imagingoligometastatic diseasesurgical resection

Identifiers

PMID40429390
PMCPMC12111963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.